BR100 Increased By (0.02%)
BR30 Increased By (0.06%)
KSE100 Decreased By (-0%)
KSE30 Increased By (0.05%)
BECO 5.52 Decreased By ▼ -0.02 (-0.36%)
BML 56.70 Decreased By ▼ -0.39 (-0.68%)
BOP 35.20 Decreased By ▼ -0.01 (-0.03%)
CNERGY 8.15 Decreased By ▼ -0.05 (-0.61%)
DCL 11.61 Decreased By ▼ -0.03 (-0.26%)
FCCL 56.61 Increased By ▲ 0.12 (0.21%)
FCSC 5.38 Increased By ▲ 0.06 (1.13%)
FFL 17.95 Decreased By ▼ -0.11 (-0.61%)
FNEL 1.29 No Change ▼ 0.00 (0%)
HUMNL 11.10 Decreased By ▼ -0.09 (-0.8%)
KEL 8.39 Increased By ▲ 0.19 (2.32%)
KOSM 6.63 Decreased By ▼ -0.04 (-0.6%)
MLCF 101.06 Increased By ▲ 0.30 (0.3%)
NBP 202.44 Decreased By ▼ -0.56 (-0.28%)
PACE 11.42 Decreased By ▼ -0.07 (-0.61%)
PAEL 43.32 Increased By ▲ 0.24 (0.56%)
PIAHCLA 27.24 Increased By ▲ 0.24 (0.89%)
PIBTL 17.82 Decreased By ▼ -0.02 (-0.11%)
PPL 244.79 Increased By ▲ 2.16 (0.89%)
PRL 35.71 Decreased By ▼ -0.16 (-0.45%)
PTC 65.45 Decreased By ▼ -0.40 (-0.61%)
SEARL 93.55 Decreased By ▼ -0.03 (-0.03%)
SSGC 32.98 Increased By ▲ 0.75 (2.33%)
TELE 9.04 Decreased By ▼ -0.07 (-0.77%)
THCCL 66.80 Increased By ▲ 0.31 (0.47%)
TPLP 10.85 Decreased By ▼ -0.10 (-0.91%)
TREET 25.48 Decreased By ▼ -0.24 (-0.93%)
TRG 65.90 Decreased By ▼ -0.05 (-0.08%)
WAVES 11.13 Decreased By ▼ -0.03 (-0.27%)
WTL 1.27 Increased By ▲ 0.01 (0.79%)
اردو
Android App
Print Edition Dollar to PKR
Budget 2026-27 Iran-US war Petrol Prices Gold Rates Podcasts PSX Notices
Business & Finance

Bayer agrees to help make CureVac's COVID-19 vaccine

  • Bayer said it expects to produce 161 million doses of CureVac's experimental vaccine.
Published February 1, 2021 Updated February 1, 2021 02:58pm
Save
1 min
comment
By Reuters
Add BRecorder as a trusted
source on Google
Google Preferred Source

BERLIN: German pharmaceutical giant Bayer said on Monday it will help CureVac produce its experimental COVID-19 vaccine, the latest drugmaker to offer up manufacturing capacity as supplies fall behind demand.

Bayer said it expects to produce 161 million doses of CureVac's experimental vaccine, which is currently in late-stage testing, in 2022, its head of pharma Stefan Oelrich told a news conference.

drugmaker COVID19

Comments

Comments are closed for this article.

More Stories

Browse all stories